U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07816978) titled 'Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism' on Sept. 02.
Brief Summary: High-risk pulmonary embolism is a life-threatening condition requiring immediate reperfusion therapy. Full-dose systemic thrombolysis is recommended as first-line treatment, but its use is limited by the risk of major bleeding, including intracranial hemorrhage. Reduced-dose systemic thrombolysis may reduce bleeding while maintaining clinical efficacy, but this strategy has not been adequately evaluated in patients with high-risk pulmonary embolism.
REDSTEM is an international, multicenter, randomized, adaptive, open-label, blinde...